ME:DAM

Product Overview

ME:DAM, also known as MEDAM or HYAFILIA ME:DAM, is a South Korean cross-linked hyaluronic acid (HA) dermal filler developed and manufactured by CHA Meditech Co., Ltd. The product family includes three formulations—ME:DAM Light, ME:DAM Prime, and ME:DAM Deep—distinguished by their gel viscosity, elasticity, and intended aesthetic applications. Each formulation contains 20 mg/mL hyaluronic acid and is commercially supplied in a 1 mL pre-filled syringe.

ME:DAM was introduced in 2021 as an advancement of CHA Meditech's established HYAFILIA dermal filler technology. The product family incorporates the company's proprietary HA cross-linking expertise and features an ergonomically designed syringe developed to support controlled handling by medical professionals.

The ME:DAM range provides three gel profiles for different facial wrinkle and contouring requirements. Light is positioned for fine lines and superficial correction, Prime for moderate wrinkles and facial folds, and Deep for deeper folds and structural volume restoration.

The standard ME:DAM Light, Prime, and Deep formulations are distinguished from the separately marketed ME:DAM Plus range, which contains lidocaine. This page focuses on the three standard formulations without added lidocaine.

This TEOSQUARE product page provides professional buyers with information about ME:DAM's composition, formulation technology, product variants, packaging specifications, and regulatory considerations.

Key Features

• 20 mg/mL Hyaluronic Acid: Formulated with cross-linked hyaluronic acid at a reported concentration of 20 mg/mL across the Light, Prime, and Deep product range.
• Three Gel Formulations: Available in Light, Prime, and Deep variants, differentiated by their intended viscoelastic properties and facial correction characteristics.
• Advanced HA Cross-Linking Technology: Developed using CHA Meditech's hyaluronic acid cross-linking technology, with a formulation concept emphasizing gel cohesivity and structural stability.
• Ergonomic Syringe Design: Features a manufacturer-developed syringe design intended to improve grip stability and handling during professional procedures.
• 1 mL Pre-Filled Syringe: Each standard commercial presentation contains one pre-filled syringe with a nominal volume of 1 mL.
• South Korean Manufacturer: Developed and manufactured by CHA Meditech Co., Ltd., a member of the CHA healthcare and biotechnology group.

Composition & Specifications

ME:DAM is based on cross-linked hyaluronic acid, a hydrophilic polymer used in injectable soft-tissue fillers to provide temporary physical volume and tissue support.

The Light, Prime, and Deep variants share the same principal ingredient but differ in their formulation characteristics. These differences influence their commercial positioning for fine wrinkles, moderate facial folds, and deeper volume correction.

Cross-Linked Hyaluronic Acid

Hyaluronic acid is a naturally occurring glycosaminoglycan found in the extracellular matrix of human tissues. Its molecular structure enables it to bind water and contribute to tissue hydration, viscoelasticity, and mechanical support.

In dermal fillers, HA undergoes chemical cross-linking to form a stabilized gel network. This process modifies the material's physical characteristics and increases its resistance to degradation compared with non-cross-linked hyaluronic acid.

ME:DAM contains cross-linked HA at a reported concentration of 20 mg/mL. The formulation is designed to provide temporary physical volume through the presence of a hydrated gel within soft tissue.

BDDE Cross-Linking Technology

BDDE, or 1,4-butanediol diglycidyl ether, is a chemical cross-linking agent widely used in the manufacture of hyaluronic acid dermal fillers.

BDDE creates chemical connections between HA polymer chains, producing a gel network with modified elasticity, viscosity, and resistance to degradation.

CHA Meditech states that its ME:DAM manufacturing technology is designed to minimize residual BDDE while improving the cohesivity and stability of the HA gel.

The exact residual BDDE concentration and cross-linking parameters of individual ME:DAM formulations should be confirmed from manufacturer-issued technical and quality documentation.

Viscosity, Elasticity, and Cohesivity

The performance of an HA dermal filler depends on several physical characteristics beyond its hyaluronic acid concentration.

Viscosity describes resistance to flow, elasticity describes the ability of a gel to recover after deformation, and cohesivity describes the tendency of the gel to remain together under mechanical forces.

ME:DAM Light, Prime, and Deep are distinguished by their intended rheological profiles. This allows the product family to offer different gel characteristics while maintaining a consistent principal ingredient.

Numerical measurements such as storage modulus (G'), loss modulus (G''), and cohesivity values should be obtained from product-specific technical data when a quantitative comparison is required.

The information above describes the HA-based formulation and manufacturer-reported technology. Exact quantitative properties should be verified against the technical documentation for each supplied ME:DAM variant.

How ME:DAM Hyaluronic Acid Filler Works

ME:DAM uses cross-linked hyaluronic acid to provide temporary physical volume and support within soft tissue. Its primary mechanism involves the mechanical properties of the implanted HA gel rather than permanent tissue regeneration.

Physical Volume Restoration

Cross-linked hyaluronic acid forms a hydrated gel that can occupy space within soft tissue. This physical volume contributes to the correction of certain wrinkles, folds, and soft-tissue depressions when used within the product's authorized indications.

The degree of correction depends on the formulation's physical characteristics, tissue environment, and individual anatomical factors.

Gel Stability and Structural Support

The cross-linked polymer network provides the gel with viscoelastic characteristics that influence its resistance to deformation and ability to maintain shape.

CHA Meditech describes ME:DAM as an advancement of its HYAFILIA filler technology, emphasizing improved gel cohesivity and shape retention.

These are manufacturer-described formulation characteristics. They do not independently establish superiority over competing HA fillers or guarantee a particular clinical outcome.

Temporary and Biodegradable Material

Hyaluronic acid is biodegradable and can undergo enzymatic and non-enzymatic degradation over time.

Chemical cross-linking generally increases resistance to degradation, but the duration of clinical effect depends on the finished product, tissue environment, anatomical location, and individual biological factors.

A single duration-of-effect estimate should not be applied to all ME:DAM variants without appropriate product-specific clinical evidence.

These mechanisms describe established properties of cross-linked HA fillers. They do not replace product-specific clinical data or establish suitability for an individual patient.

Available ME:DAM Variants

The standard ME:DAM product family consists of three formulations: Light, Prime, and Deep. They are differentiated by gel characteristics and their commercially described aesthetic applications.

All three variants contain 20 mg/mL cross-linked hyaluronic acid and are supplied in 1 mL pre-filled syringes. The standard non-Plus formulations do not include added lidocaine.

ME:DAM Light

ME:DAM Light is the softer formulation within the standard ME:DAM range. It contains 20 mg/mL cross-linked hyaluronic acid and is supplied in a 1 mL pre-filled syringe.

Its relatively low-viscosity gel profile is commercially positioned for the correction of fine facial lines and superficial wrinkles.

Published distribution information describes applications involving fine perioral wrinkles, superficial facial lines, and subtle contour refinement. These descriptions represent commercial positioning rather than authorization for every anatomical location.

The Light formulation is distinguished from Prime and Deep primarily by its intended gel characteristics, not by a different HA concentration.

ME:DAM Prime

ME:DAM Prime is the intermediate formulation within the standard ME:DAM product family. It contains 20 mg/mL cross-linked hyaluronic acid and is supplied in a 1 mL pre-filled syringe.

Prime is commercially positioned for moderate facial wrinkles and folds where an intermediate gel profile may be appropriate.

Published professional product descriptions associate ME:DAM Prime with nasolabial folds, marionette lines, and selected facial volume-correction applications.

Its gel characteristics are intended to provide a balance between flexibility and structural support. Quantitative performance differences should be evaluated using manufacturer-issued rheological measurements.

ME:DAM Deep

ME:DAM Deep is the firmer formulation within the standard ME:DAM range. It contains 20 mg/mL cross-linked hyaluronic acid and is supplied in a 1 mL pre-filled syringe.

The Deep formulation is commercially positioned for deeper wrinkles, pronounced facial folds, and applications involving greater structural volume correction.

Its relatively firm gel profile is intended to provide greater resistance to deformation than the softer formulations in the product family.

The suitability of ME:DAM Deep for a specific anatomical area depends on its approved indications, product-specific technical characteristics, and professional clinical assessment.

Standard ME:DAM vs. ME:DAM Plus

CHA Meditech introduced both standard ME:DAM and ME:DAM Plus formulations. The distinction is important because the Plus products contain lidocaine, a local anesthetic.

The standard range consists of ME:DAM Light, Prime, and Deep without added lidocaine.

The separate Plus range consists of ME:DAM Light Plus, Prime Plus, and Deep Plus. CHA Meditech's published specifications identify 20 mg/mL cross-linked HA and 3.2 mg/mL lidocaine, expressed as 3.0 mg/mL lidocaine hydrochloride, in the Plus formulations.

This product page covers the standard Light, Prime, and Deep formulations. The presence of lidocaine must be verified from the exact supplied product label rather than inferred from an abbreviated commercial product name.

Packaging & Product Presentation

ME:DAM Light, Prime, and Deep are commercially supplied as cross-linked HA gels in pre-filled syringes. The standard documented presentation contains one 1 mL syringe per box.

CHA Meditech introduced an ergonomic syringe design intended to provide improved grip stability and handling for medical professionals.

Some distributors also identify sterile needles as included packaging accessories. The exact number and specifications of supplied needles should be confirmed against the manufacturer's packaging for the selected product.

Professional buyers should verify the full product name, formulation type, HA concentration, lidocaine status, batch number, expiration date, and original manufacturer labeling.

The standard ME:DAM and ME:DAM Plus products are distinct formulations. Packaging appearance and abbreviated product names should not be used as substitutes for confirmation of the complete ingredient declaration.

Storage & Handling

ME:DAM products should be stored according to the original manufacturer-issued labeling. Published product information commonly identifies storage between 1°C and 30°C, protected from direct sunlight.

CHA Meditech directly specifies 1–30°C storage and protection from light for its ME:DAM Plus formulations. The applicable storage instructions for each standard non-Plus product should be confirmed using its own original labeling.

• Storage Temperature: Follow the temperature range specified on the supplied product label.
• Light Protection: Protect the product from direct sunlight.
• Freezing Precautions: Do not freeze the product unless explicitly permitted by its manufacturer-issued instructions.
• Original Packaging: Keep the syringe in its original packaging until required for authorized professional use.
• Packaging Integrity: Inspect the syringe and sterile barrier for damage or other signs of compromised integrity.
• Product Traceability: Confirm the variant, batch number, expiration date, and manufacturer information before professional handling.

A shelf life of 36 months is commonly reported for ME:DAM products and is directly documented by CHA Meditech for the Plus range. The applicable shelf life of the selected standard formulation should be verified from its original packaging.

Storage and shelf-life information should be verified for the exact supplied product. Manufacturer-validated instructions take precedence over distributor descriptions.

Safety & Regulatory Considerations

ME:DAM is an injectable hyaluronic acid medical device intended for use by appropriately qualified healthcare professionals. Product selection and administration require knowledge of facial anatomy, relevant medical conditions, and potential complications.

Potential Adverse Reactions

Common adverse reactions associated with HA dermal fillers may include temporary pain, redness, swelling, tenderness, bruising, and localized inflammation.

Other reported complications of dermal filler procedures include infection, nodules, granulomatous reactions, delayed inflammation, and filler migration.

Serious complications can occur if filler enters or compresses a blood vessel. These may include vascular occlusion, tissue ischemia, necrosis, visual impairment, blindness, or other severe injuries.

Material and Formulation Considerations

ME:DAM contains cross-linked hyaluronic acid. Although HA is a naturally occurring biological material, its use in an injectable medical device does not eliminate the possibility of adverse reactions.

Cross-linking chemistry, residual processing substances, gel characteristics, and the complete finished formulation are relevant to product safety.

The three ME:DAM formulations differ in their intended mechanical characteristics. They should not be treated as clinically interchangeable solely because they contain the same nominal HA concentration.

Regulatory Authorization

ME:DAM was developed by CHA Meditech and introduced to the South Korean medical aesthetics market as part of the HYAFILIA dermal filler portfolio.

The manufacturer classifies its HA filler products as medical devices. However, regulatory authorization is product- and jurisdiction-specific.

Authorization in South Korea does not automatically establish approval in the United States, European Union, or other markets. Professional buyers should verify the registration status, approved indications, labeling, and lawful distribution requirements of the exact ME:DAM variant in their destination country.

This description is intended for professional product identification and comparison. It does not provide injection instructions, establish patient suitability, or authorize use beyond the applicable product labeling.

Frequently Asked Questions